Foscavir
(Foscarnet sodium)ApprovedSmall molecule
Foscarnet sodium is used to treat serious viral infections, particularly cytomegalovirus (CMV) infections in people with weakened immune systems, and herpes simplex virus infections that don't respond to other treatments.[2] Foscavir is currently approved and in use across 6 indications[4].[1]
Foscavir is one of 93 small molecule programs targeting Cytomegalovirus Retinitis. It is currently in Approved.
6
Indications
24
Total Trials
1
Active Trials
92
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
350 competitors in Treatment
#DrugCompanyPhaseTrials
1Foscavir
CClinigen, Inc.
Approved
Dexilant
TakedaPreclinical
Theo-Dur
PfizerPreclinical
Lamprene
NovartisPreclinical
Levulan
Sun Pharmaceutical Industries, Inc.Preclinical
Sirturo
WWim Janssens
Preclinical
Lotemax
PPharmos
Preclinical
Norpramin
VValidus Pharmaceuticals
Preclinical
Barhemsys
Tibotec Pharmaceuticals, IrelandPreclinical
Rabbit Anti-Thymocyte Globulin
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment6 trials
Comparison of Two Methods in the Treatment of Cytomegalovirus of the Eyes in Patients With AIDS
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001061·167 enrolled
Show 3 more trials
CMV Retinitis Retreatment Trial
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000766·300 enrolled
Cytomegalovirus (CMV)3 trials
Immunodeficiency3 trials
Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000726·53 enrolled
Scar2 trials
The Effect of Stomach Acid on Foscarnet
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000964·6 enrolled
Safety and Efficacy1 trial
9 more indications
Cytomegalovirus Infection1 trial
Complication1 trial
Herpes Zoster1 trial
Intravenous1 trial
Gastrointestinal1 trial
Herpes Simplex Virus1 trial
HIV infection1 trial
A Study of Foscarnet in the Treatment of HIV Infection in Patients Who Have Taken Zidovudine for a Long Time
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001002·12 enrolled
Myelosuppression1 trial
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000691·156 enrolled
Cytomegalovirus (CMV) Infection1 trial
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
Active, not recruiting·—··NCT01199562·153 enrolled
Regulatory
FDA Approval Timeline[5]
Sep 27, 1991
FOSCAVIR
NDA NDA020068
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Foscavir drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Foscarnet sodium. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Human Herpesvirus 1 DNA Polymerase Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- CClinigen, Inc.